Objectives: In 2010, the US Advisory Committee on Immunization Practices recommended 7-valent pneumococcal conjugate vaccine (PCV7) be replaced by 13-valent vaccine (PCV13) for routine use in a four-dose series at 2, 4, 6, and 12-15 months of age. Published analyses estimated that PCV13 implementation would be cost-saving in aggregate, but the net economic impact on particular payers is unknown. We disaggregated the expected costs and savings by payer to determine the net costs for public and private payers over a 10-year horizon. MethOds: A Markov model was used to simulate vaccination and pneumococcal disease events and their related costs with PCV13 compared to PCV7 from 2010 to 2019. The PCV13 strategy included a one-time catch-up dose in 2010 for children who had completed the PCV7 series. Disease reductions both in vaccinated and other age groups were modeled based on PCV7 efficacy and effectiveness data. Medical costs related to pneumococcal disease were allocated to public (Medicare; Medicaid; military) or private payers using age-specific health care insurance coverage survey data. Vaccine program costs were allocated based on sales data. All costs were measured in 2013 US dollars. Results: In the simulation, 40.3 million(M) children participated in routine vaccination while 5.8M received a catch-up dose in the PCV13 strategy. The PCV13 strategy prevented an additional 121,300 cases of invasive pneumococcal disease, 3.3M of pneumonia and 17.6M of acute otitis media compared to PCV7 over 10 years. Public and private payers will pay $3.5 billion(B) and $2.6B, respectively, for the vaccine but accrue $6.1B and $4.2B in overall savings. While the magnitude of savings varied in sensitivity analyses, implementation of PCV13 remained cost-saving for all payers. cOnclusiOns: The currently-recommended PCV13 pediatric program is cost-saving for both public and private payers. Net savings were greater for public payers, despite higher vaccine costs.
PIN26 budgET ImPACT ANAlySIS OF dOluTEgrAvIr IN ThE TrEATmENT OF humAN ImmuNOdEFICIENCy vIruS (hIv) IN ONTArIO, CANAdA
Monga N. 1 , Cui Q. 1 , Maschio M. 2 , Becker D. L. 2 , de los Rios P. 3 , Ismaila A. 4 1 GlaxoSmithKline, Mississauga, ON, Canada, 2 OptumInsight, Burlington, ON, Canada, 3 ViiV Healthcare, Laval, QC, Canada, 4 GlaxoSmithKline, Research Triangle Park, NC, USA Objectives: To estimate the budgetary impact of adding dolutegravir to the Ontario Drug Benefit Formulary (ODBF) for a three-year period for the treatment of HIV infection in adults and children (≥ 12 years of age). MethOds: Three discrete populations were considered: treatment-naïve (TN) patients staying on their first line, TN switchers (assumed switches within the first 6 months of antiretroviral therapy (ART) initiation) and treatment-experienced (TE) patients. Epidemiology data were obtained from published sources. Ontario-specific data and analysis from the IMS Brogan Database were used to estimate the proportion of patients who were treated and covered by the ODBF, proportions of patients remaining on their first regimen after ART initiation over time, comparators and historical market share data. ART drug costs were calculated based on the dosage of each regimen component from the respective product monographs and unit costs from the ODBF. The budget impact was calculated for the whole HIV population and separately for each population. Sensitivity analyses were conducted on five key input parameters. Results: Out of the 12 comparators, dolutegravir-containing regimens were assumed to take market shares from 6 regimens: Atripla, Truvada⁄Prezista⁄Norvir, Truvada⁄Isentress, Truvada⁄Reyataz⁄Norvir, Kivexa⁄Isentress and Stribild. Adding dolutegravir to the list of reimbursed ARTs on the ODBF will result in incremental savings in each of the three years following the listing date of $2,717,585, $5,181,704, and $8,040,076 for a total savings of $15,939,365. The analysis was somewhat sensitive to assumptions made regarding HIV incidence and prevalence and the proportion treated with drug benefits. Based on the accuracy of the assumptions made in this analysis, the total savings to the budget over a three-year period may range between $12,751,492 and $19,127,238. cOnclusiOns: The addition of adding dolutegravir to the ODBF will result in a significant net savings through the displacement of more expensive regimens in Ontario. Objectives: The prevalence of systemic Candida infection (SCI) caused by non-albicans species, which display greater resistance to azole antifungal agents, is increasing. Treatment with broad-spectrum antifungal agents, such as echinocandins, with subsequent switch to fluconazole if isolates are shown to be sensitive ('de-escalation') is recommended by treatment guidelines. We developed a model to assess the budget impact of the de-escalation strategy in France and Germany. MethOds: The budget impact of initial micafungin treatment in a de-escalation strategy versus fluconazole in an escalation strategy was modelled using decision analysis based on data from relevant studies and a cost-effectiveness analysis. Duration of appropriate treatment was 14 days, meaning that treatment outcome was assessed after 14 days, or 17 days if fluconazole had to be switched once fluconazole sensitivity was known (after 3 days of therapy). Clinical success was defined as resolution or reduction of all signs, symptoms and radiographic abnormalities associated with SCI at treatment end. Results: In France and Germany, the incidence of SCI was estimated at 28
PIN27 'dE-ESCAlATION' uSINg mICAFuNgIN FOr ThE TrEATmENT OF SySTEmIC
Objectives: Azithromycin has an attractive safety profile in treating or preventing certain bacterial infections. However, there is growing concern that Azithromycin may be associated with increased cardiovascular risk and lead to cardiovascular death in high risk patients. We therefore conducted a meta-analysis of randomized Controlled trials to describe the cardiovascular risk profile of those patients receiving Azithromycin. MethOds: The MEDLINE and Cochrane Central Register of Controlled Trials databases were searched from 1991 to September 2013 using specific search terms for English-language trials of comparing high baseline risk of cardiovascular disease patients receiving Azithromycin or placebo and have reported cardiovascular outcomes. Abstracts from major scientific meetings were also reviewed.In the analysis, Methods based on odds ratios (ORs) was used. OR was calculated using a random-effects model (because we assume that the treatment effect in all the included studies are not identical) from the ORs and 95% confidence intervals (CIs) were used for each end point in each study. Statistical heterogeneity scores were assessed with an I4 2 test. Sensitivity analyses were performed by removing some trials and recalculating the combined ORs for the remaining studies. Results: 12 trials randomized a total of 15,588 patients into two groups, treatment and placebo. Treatment effect on any cardiovascular outcome was not significantly different in any of the nine trials. For all trials combined, the pooled odds ratio for mortality was not significantly different [(OR, 0.873; 95% CI, 0.743-1.027), p = 0.102]. No heterogeneity was observed (I 2 = 0). Similarly, there was no difference in the pooled odds ratio for hospitalization and coronary intervention [(OR, 1.021; 95% CI, 0.882-1.182), p = 0.774, I 2 = 0%] and [(OR, 0.998; 95% CI, 0.885-1.125), p = 0.982, I 2 = 0%], respectively. cOnclusiOns: The findings of this systematic review suggest that no significant relationships exist between Azithromycin and risk of cardiovascular events in high risk patients.
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ANTImICrObIAlS: A mAjOr ClASS OF drugS CAuSINg AdvErSE drug rEACTIONS IN ThE ICuS OF AN INdIAN PublIC TEAChINg hOSPITAl
Kandukuri P. 1 , Tiwari P. 2 , Gombar S. 3 , D'cruz S. 3 , Sachdev A. 3 1 National Institute of Pharmaceutical Education and Research, Mohali, India, 2 National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, India, 3 Government Medical College and Hospital, Chandigarh, India Objectives: Patients in the intensive care unit (ICU) have multiorgan dysfunction as well as altered pharmacokinetic parameters. Hence, they are more susceptible to adverse drug reactions (ADRs). The objective of the study was to identify the major class of drugs involved in causing ADRs in ICU patients of an Indian public teaching, tertiary care hospital. MethOds: A prospective observational study was conducted in the ICUs of a public teaching hospital. All the relevant data was collected from the patients case records in a standard data collection format and the patients were followed until discharge or transferred from the ICUs. ADRs were identified based on the subjective findings, objective findings and spontaneous reporting. The drugs responsible for causing ADR were identified and classified using Anatomic, Therapeutic and Chemical(ATC) classification. Results: The results of this 12 week study were based upon the data obtained from 70 patients(37 males, 33 females). Only 10 patients developed ADRs. The drugs causing ADRs were classified using the ATC classification. This showed that the most common ADR causing drugs belonged to the class of infections and infestations (30%), cardiovascular system(14%), endocrine system(14%), respiratory system (14%) and others (14%), followed by Brain and nervous system (7%), blood and blood forming agents (7%) accounting for least number of ADRs. cOnclusiOns: In this pilot study, Antimicrobials was found to be the most common class of drugs causing ADRs. We studied small number of patients, it is suggested that future large scale studies should be done to further gain insight into the ADRs. Control and Prevention, Atlanta, GA, USA, 4 Cerner Corporation, North Kansas City, MO, USA, 5 University of Illinois at Chicago, Chicago, IL, USA, 6 Infectious disease Research Institute, Tampa, FL, USA Objectives: Higher plasma CD4 cell counts per mm 3 at ART initiation (AI-CD4) improve long-term CD4 responses and survival. Recent data suggest CD4 > 750 is a clinically significant threshold for AIDS-related illness reduction and immune "normalization". We evaluated the effect of AI-CD4 on achieving CD4 > 750 and mortality risk. MethOds: Among HIV Outpatient Study patients seen during 1996-2012 for three or more years after AI, we analyzed CD4 trajectories and mortality rates per 100 persons-years (MR) by AI-CD4, and the association of AI-CD4 with achieving CD4 > 750 ("normalization") using Kaplan-Meier methods and Cox proportional hazards models. Results: Of 1327 eligible patients followed a median of 7.9 years, > 85% received HAART ≥ 75% of follow-up time, and 64 died. Higher AI-CD4 was associated with increased median peak CD4 (p < 0.001). Maximal CD4 response and benefit plateaued at eight years, but differences by AI-CD4 persisted (p < 0.001). Lower crude MRs (p = 0.005) and higher CD4 closest to death (p = 0.013) were associated with higher AI-CD4. Increases in median CD4 for persons with AI-CD4 < 50 and 50-199 converged by eight years (< 50% achieved CD4 > 750) whereas patients with AI-CD4 > 350 normalized by eight years (> 80% of patients). In multivariable analyses, higher AI-CD4 was the only factor independently associated with achieving CD4 normalization during follow-up. cOnclusiOns: Progressively higher AI-CD4 predicted greater long-term CD4 gains, achieving CD4 normalization, increased crude survival rates, and higher CD4 at death. CD4 gains and chances of reaching CD4 normalization peaked at eight years after AI. Most with AI-CD4 > 350 eventually achieved CD4 normalization while less than half with AI-CD4s < 50 and 50-199 did. AI-CD4 ≥ 500 optimized the likelihood of CD4 normalization confirming the hazards of delayed and support AI at CD4 ≥ 500.
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